Sarcoma

Top Story

‘Cancer-agnostic’ NTRK inhibitor approval ushers in paradigm of personalized genomics-guided therapeutics

‘Cancer-agnostic’ NTRK inhibitor approval ushers in paradigm of personalized genomics-guided therapeutics
HemOnc Today, January 10, 2019
Patrick C. Ma, MD, MSc
Feature

NIH grant to fund study of fertility planning tool for cancer survivors

December 21, 2018
The NIH awarded a 5-year, $693,000 grant to The Feinstein Institute for Medical Research to develop and test a digital health platform to help young female cancer…
In the Journals Plus

Expanded use of solid tumor chemotherapy drives excess risk for certain blood cancers

December 20, 2018
Rates of therapy-related myelodysplastic syndrome and acute myeloid leukemia have risen significantly in the modern era following chemotherapy for nearly all solid tumor…
In the Journals Plus

Sorafenib improves PFS in refractory desmoid tumors

December 20, 2018
Patients with progressive, refractory or symptomatic desmoid tumors derived a significant PFS benefit from sorafenib, according to results of a double-blind…
More Headlines »
CME CPE CNE

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be…
More »
Video

Baseball star who survived melanoma ‘suffering’ from lack of sunscreen use

September 22, 2017
More »
CME CNE

Improving Colorectal Cancer Screening and Prevention: Advances in Polyp Detection and Resection

This activity is supported by an educational grant from Aries Pharmaceuticals, Inc.

Colorectal cancer (CRC) is the third most common type of cancer worldwide and the second deadliest form of cancer in…
More »